Thrombotic microangiopathy syndromes

Cancer Treat Res. 2009:148:115-36. doi: 10.1007/978-0-387-79962-9_8.
No abstract available

Publication types

  • Review

MeSH terms

  • ADAM Proteins / deficiency
  • ADAM Proteins / immunology
  • ADAM Proteins / physiology
  • ADAMTS13 Protein
  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use
  • Autoantibodies / immunology
  • Bevacizumab
  • Hematopoietic Stem Cell Transplantation / adverse effects
  • Humans
  • Immunosuppressive Agents / adverse effects
  • Immunosuppressive Agents / therapeutic use
  • Neoplasms / blood
  • Neoplasms / drug therapy
  • Plasma Exchange
  • Postoperative Complications / etiology
  • Thrombotic Microangiopathies* / chemically induced
  • Thrombotic Microangiopathies* / epidemiology
  • Thrombotic Microangiopathies* / etiology
  • Thrombotic Microangiopathies* / physiopathology
  • Thrombotic Microangiopathies* / therapy
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Autoantibodies
  • Immunosuppressive Agents
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • Bevacizumab
  • ADAM Proteins
  • ADAMTS13 Protein
  • ADAMTS13 protein, human